Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster viewing 06

YO5 - Complete Radiologic and Pathologic Response in a Metastatic Gallbladder Adenocarcinoma Patient treated with Checkpoint Inhibitor/Chemotherapy Combination: A Case Report

Date

03 Dec 2022

Session

Poster viewing 06

Topics

Tumour Site

Hepatobiliary Cancers

Presenters

Tisha Gay Tancongco

Authors

T.G.C. Tancongco1, R. Ong Abrantes2, M.R. Homez3, M..T. Bernardo4, S.M. Ramos5, A.G.A. Lui6

Author affiliations

  • 1 Medical Oncology, SPMC - Southern Philippines Medical Center, 8000 - Davao City/PH
  • 2 Division Of Hepatopancreatobiliary Surgery, Department Of Surgery, SPMC - Southern Philippines Medical Center, 8000 - Davao City/PH
  • 3 Department Of Surgery, Davao Doctors Hospital, 8000 - Davao City/PH
  • 4 Internal Medicine, Davao Doctors Hospital, 8000 - Davao City/PH
  • 5 Department Of Pathology, SPMC - Southern Philippines Medical Center, 8000 - Davao City/PH
  • 6 Internal Medicine Medical Oncology, MDMRC - Metro Davao Medical and Research Center, 8000 - Davao City/PH

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract YO5

Case summary

Complete Response in a Metastatic Gallbladder Adenocarcinoma Patient treated with Checkpoint Inhibitor/Chemotherapy Combination: A Case Report

Gallbladder Carcinoma is a rare malignancy with an overall incidence of 3 per 100,000. Prognosis is poor with a median overall survival of 11.7 months. This is attributed to aggressive tumor biology and advanced stages at diagnosis. The standard treatment of advanced gallbladder carcinoma is gemcitabine-based combination (gemcitabine-cisplatin). Recently, the superiority of adding the immune checkpoint inhibitor durvalumab to gem/cis was shown in the TOPAZ-1 trial. This case report highlights promising results on the use of durvalumab in advance gallbladder adenocarcinoma.

This is a case of a 64-year-old male who presented with abdominal pain. CT scan of the whole abdomen revealed cholecystolithiasis with cholecystitis, intraluminal hyperdense mass, consider gallbladder malignancy. Patient underwent exploratory laparotomy with frozen section biopsy which showed peritoneal fluid positive for adenocarcinoma. Intraoperatively, the gallbladder mass was unresectable, with a post operative diagnosis of Gallbladder Adenocarcinoma Stage IV. Subsequently, the patient was treated with Durvalumab (1500mg on day 1), Gemcitabine (1000mg/m2 on days 1 and 8) and cisplatin (25mg/m2 on days 1 and 8) every 3 weeks for 8 cycles.

After 8 cycles of systemic chemotherapy, a follow-up CT scan revealed complete regression of the intraluminal gallbladder mass. PET/CT scan also showed no evidence of hypermetabolic recurrent and metastatic disease. Patient underwent resection of the gallbladder mass with pathologic findings of negative for residual tumor cells, chronic cholecystitis with mucosal erosion and chemotherapy induced histologic changes.

This case report highlights the rare but possible complete pathologic response with the use of immune checkpoint inhibitor durvalumab and gemcitabine/cisplatin combination in advanced gallbladder adenocarcinoma. This is consistent with results of the TOPAZ1 trial demonstrating promising efficacy and improved outcomes with checkpoint inhibitors.

Clinical trial identification

Editorial acknowledgement

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.